Patents

U.S. Patent Board Awards Enzo Biochem Judgment in Patent Interference after Princeton University Concedes Priority

Published in Lab Business Week, March 25th, 2007

Enzo Biochem, Inc. (NYSE: ENZ) announced that the Board of Patents and Interferences has entered judgment in favor of its subsidiary's patent application for nucleic acid signal amplification over two patents owned by Princeton University. Princeton had conceded priority to Enzo.

In the interference declared by the U.S. Patent and Trademark Office in August 2006, Enzo Life Sciences was named the senior party and Princeton, owner of U.S. Patent Nos. 4,882,269 and 5,424,188, was the junior party. The '269 patent was licensed by Princeton to Chiron Corp., who subsequently licensed it to Bayer HealthCare, LLC.

Another interference involving the same...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2007-03-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry